Effect of statins on the progression and prognosis of chronic liver diseases
DOI:10.3969/j.issn.1001-5256.2021.03.045
- VernacularTitle:他汀类药物对慢性肝脏疾病进展及预后的影响
- Author:
Shuai WANG
1
;
Yonggui ZHANG
;
Jiangbin WANG
;
Yan XU
Author Information
1. Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun 130033, China
- Publication Type:Research Article
- Keywords:
Liver Diseases;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Treatment Outcome;
Prognosis
- From:
Journal of Clinical Hepatology
2021;37(3):721-724
- CountryChina
- Language:Chinese
-
Abstract:
Chronic liver diseases can progress to liver fibrosis and cirrhosis and may lead to portal hypertension and even hepatocellular carcinoma. In recent years, more and more studies have shown that statins can improve liver histology, delay progression to liver fibrosis, and reduce the risk of decompensation and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. This article introduces the advances in the application of statins in patients with chronic liver diseases, so as to provide a basis for the prevention and treatment of chronic liver diseases.
